The majority of pediatric poisoned patients can be managed with good, sound supportive medical management. However, there are some clinical scenarios in which the timely administration of a specific antidote will save a patient's life. Antidotes are chemicals or physiological antagonists that prevent or reverse the toxic effects of specific poisonings. This reduction of toxicity may occur by altering the toxin, reducing the concentration of the toxin, preventing the toxin from reaching its effector site or reducing the toxin's action at its effector site. Most healthcare providers are familiar with traditional antidotes such as naloxone for opioid poisoning, Nacetylcysteine for acetaminophen toxicity, deferoxamine for iron poisoning, and oxygen for carbon monoxide poisoning. There are older antidotes that are making a resurgence in the clinical treatment of poisoned patients. There are new antidotes whereby scientific evidence is demonstrating their effectiveness in reversing toxicity. There are traditional antidotes that are being used for new indications. Finally, there is what used to be known as a 'universal antidote', whose use and complications are being re-examined.
The word antidote is derived from the Greek word antidotos, meaning a remedy to counteract a poison. The use of poisons in Ancient Greece and Rome was accompanied by a concomitant search for a universal antidote. One of the earliest specific references to a protective agent against a poison can be found in Homer's Odyssey, where Ulysses is advised to protect himself by taking the antidote 'moli'. Speculation suggests that moli referred to Galanthus nivalis, a naturally occurring cholinesterase inhibitor. This agent could have been used as an antidote against poisonous plants such as Datura stramonium,or Jimson weed [1] . This plant causes anticholinergic toxicity.
Physostigmine is an antidote that has been used to treat anticholinergic toxicity for over a century. Physostigmine was the first cholinesterase inhibitor, the first effective drug for glaucoma (used in 1877), and the first effective treatment for myasthenia gravis. Dr Nan Frascogna (pp. 000-000) provides an excellent overview of anticholinergic toxicity and its pathophysiology, as well as the indications and contraindications for physostigmine based on the scientific literature. Although the evidence is virtually nonexistent for pediatrics, the adult studies can be extrapolated to the pediatric population where the anticholinergic toxidrome is the same. Physostigmine is not an antidote that the pediatric practitioner will use often; however, it is important for the clinician to become familiar with its indications and dosing as its use may not only obviate the need for expensive diagnostic testing in a child with an anticholinergic toxidrome, but also prevent complications from agitated delirium, such as hyperthermia and rhabdomyolysis, by reversing the clinical state.
With the exception of the benzodiazepines, there are virtually no specific antidotes for any of the anticonvulsants except for valproic acid. Although flumazenil is a pure benzodiazepine antagonist, it is not recommended for benzodiazepine overdoses as it may precipitate seizures in persons who are benzodiazepine-dependent, persons who have a seizure disorder, or persons who have co-ingested medications with epileptogenic potential such as cyclic antidepressants, bupropion, or isoniazid. Carnitine is relatively new in the world of antidotal therapy and especially important in the pediatric population as so many children are on this drug not only for seizures but for other disorders such as migraine headaches. Dr Scott Russell (pp. 000-000) presents an overview of the pathophysiology of valproic acid toxicity and the rationale for carnitine's beneficial effects in acute valproate overdose.
Unfortunately, children remain potential victims of chemical terrorism. In 2002, more than 40 children became ill with nicotine poisoning -nausea, mouth burning, vomiting -after eating ground beef from a grocery store in Grand Rapids, Michigan, USA. A disgruntled grocery-store worker had placed a nicotine-containing insecticide in the beef. Ultimately, more than 100 people became ill, in what is now considered the largest act of chemical terrorism in US history. Since the horrific and devastating events of 11 September 2001, numerous public health and healthcare initiatives have been developed and implemented to address the protection and treatment of people following a terrorist incident. However, many of these initiatives are inadequate in ensuring the protection of children.
It is imperative that pediatricians be knowledgeable about the chemical and biological weapons that could be used against a population which includes children. Pediatric healthcare providers should also be familiar with general management issues from toxicity secondary to these weapons as they may ultimately be involved in their care. The American Academy of Pediatrics recently published their policy statement, Chemical-biological terrorism and its impact on children, which provides an excellent overview of chemical agents, syndromic surveillance, system issues in preparedness for terrorism, and recommendations for pediatricians [2] .
Management of nerve-agent exposures includes aggressive supportive care, triage of victims, decontamination if appropriate, and prompt administration of antidotal therapy when indicated. Atropine and pralidoxime are old antidotes 'traditionally' used for toxicity secondary to organophosphorous compounds and carbamates which are compounds found in many pesticides. Dr Mark Baker (pp. 000-000) discusses the toxicity of nerve agents, availability of pediatric autoinjectors, and guidelines/ evidence for dosing administration of these two antidotes.
The Greeks referred to the universal antidote as the alexipharmica or theriac. The term alexipharmica was derived from the words alexipharmakos, that which keeps off poison, and antipharmakon or antidote. Alexipharmica was increasingly used to refer to a method of treatment, such as the induction of emesis by using a feather [3] . Starting in the 5th century BC, terra sigillata or sacred sealed earth, an adsorbent agent, was also promoted as the universal antidote. This agent consisted of red clay which could be found only on the Greek island of Lemnos and was advocated as effective in counteracting all poisons. Throughout history, there were many other agents touted as universal antidotes: bezoar stones (intestinal calculi), toadstones, and the mythical unicorn horns.
The principle of charcoal being used as an adsorptive agent was first described in the 18th century. Its role as an antidote in the treatment of poisoning was first demonstrated in the early 19th century when the French chemist M. Bertrand survived an ingestion consisting of 5 g of arsenic trioxide that had been mixed with charcoal. In 1831, the pharmacist P.F. Touery survived an ingestion consisting of 10 times the lethal dose of strychnine mixed with 15 g of charcoal. The first charcoal-efficacy studies in humans were performed by the American physician B. Rand in the mid-1800s.
In the 20th century, the universal antidote denoted an agent used for gastrointestinal decontamination. For many years it was sold under the trade name of Unidote and Res-Q and had become a 'traditional' antidote and advocated as standard management of the poisoned patient. Commercial preparations consisted of one part magnesium oxide, one part tannic acid and two parts activated charcoal. Combination therapy like this preparation was speculated to offer a broader spectrum of action than activated charcoal alone by neutralizing acids (magnesium oxide) and precipitating alkaloids and metals (tannic acid) [4] . The use of this universal antidote declined by the mid-1980s and it is no longer available. Furthermore, studies demonstrating activated charcoal's superiority to the previous universal antidote in decreasing absorption of various substances and the recognition of the potential hepatotoxicity of tannic acid further promoted the abandonment of the combination product and the use of activated charcoal alone as a universal antidote.
In his article, Dr Robert Lapus (pp. 000-000) reviews the literature on charcoal's efficacy and safety as an adsorbent, its indications, and its complications. The 'reflex use' of charcoal for every potentially poisoned patient is not advocated. Its efficacy significantly decreases after 1 h for most substances that do not delay gastric emptying. Furthermore, in pediatric unintentional ingestions, where the outcomes are usually mild, it is important to examine the risk/benefit ratio of administering activated charcoal. With ingestions of liquids and one or two pills in the pediatric patient, charcoal is rarely indicated once the patient reaches the healthcare facility.
